223 related articles for article (PubMed ID: 6196789)
61. Interferons and cancer: the end of the beginning or the beginning of the end?
Priestman TJ
Clin Oncol; 1981 Dec; 7(4):271-4. PubMed ID: 6172229
[No Abstract] [Full Text] [Related]
62. Interferon: a patient speaks.
Can Nurse; 1983 Feb; 79(2):21. PubMed ID: 6186362
[No Abstract] [Full Text] [Related]
63. [Recent findings in the field of oncological therapy with interferon].
Pugliese A; Vitale M; Cosseta P
G Batteriol Virol Immunol; 1981; 74(7-12):308-19. PubMed ID: 6182049
[No Abstract] [Full Text] [Related]
64. [Interferons--research, effects and importance].
Lodemann E
Naturwissenschaften; 1984 Nov; 71(11):547-51. PubMed ID: 6084176
[TBL] [Abstract][Full Text] [Related]
65. Nursing management of patients receiving interferon.
Hahn MB; Jassak PF
Semin Oncol Nurs; 1988 May; 4(2):95-101. PubMed ID: 2453909
[No Abstract] [Full Text] [Related]
66. Interferon: history, present status.
Dugan WM
J Indiana State Med Assoc; 1979 Jan; 72(1):16. PubMed ID: 758348
[No Abstract] [Full Text] [Related]
67. [Cancer immunotherapy: new approaches].
Blay JY; Thomachot MC; Alberti L; Bachelot T; Voorzanger-Rousselot N; Puisieux I; Odin L; Ménétrier-Caux C
Bull Cancer; 2000 Jan; 87(1):97-106. PubMed ID: 10673638
[No Abstract] [Full Text] [Related]
68. Interferon emerging as hormone-like substance.
Panem S
JAMA; 1982 Jan 22-29; 247(4):418-21. PubMed ID: 6172603
[No Abstract] [Full Text] [Related]
69. Interferon (I): on the threshold of clinical application.
Marx JL
Science; 1979 Jun; 204(4398):1183-6. PubMed ID: 451564
[No Abstract] [Full Text] [Related]
70. Interferon: no magic bullet against cancer.
Sun M
Science; 1981 Apr; 212(4491):141-2. PubMed ID: 6163213
[No Abstract] [Full Text] [Related]
71. [Interferons. Structure, functions and therapeutic applications of interferons].
Marcellin P
Ann Med Interne (Paris); 1993; 144(8):539-47. PubMed ID: 7513979
[No Abstract] [Full Text] [Related]
72. Clinical investigation of partially pure and recombinant DNA derived leukocyte interferon in human cancer.
Gutterman J; Quesada J
Tex Rep Biol Med; 1981-1982; 41():626-33. PubMed ID: 6763369
[No Abstract] [Full Text] [Related]
73. Interferons, interferon-like cytokines, and their receptors.
Pestka S; Krause CD; Walter MR
Immunol Rev; 2004 Dec; 202():8-32. PubMed ID: 15546383
[TBL] [Abstract][Full Text] [Related]
74. Interferons in oncology.
Woll PJ; Pettengell R
Br J Clin Pract; 1997 Mar; 51(2):111-5. PubMed ID: 9158255
[TBL] [Abstract][Full Text] [Related]
75. [Interferon as a therapeutic agent].
Borecký L
Cesk Farm; 1982 Jun; 31(5):184-7. PubMed ID: 6180842
[No Abstract] [Full Text] [Related]
76. Interferon therapy.
Alexander MC
NITA; 1987; 10(1):40-2. PubMed ID: 2434885
[No Abstract] [Full Text] [Related]
77. [Interferons: physiology, pharmacology and pharmacotherapeutic perspectives].
Billiau A
J Pharmacol; 1983; 14 Suppl 3():105-16. PubMed ID: 6200731
[TBL] [Abstract][Full Text] [Related]
78. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis.
Weinstock-Guttman B; Ransohoff RM; Kinkel RP; Rudick RA
Ann Neurol; 1995 Jan; 37(1):7-15. PubMed ID: 7529476
[No Abstract] [Full Text] [Related]
79. Interferon: advances in biotherapy.
Semin Oncol; 1991 Oct; 18(5 Suppl 7):1-112. PubMed ID: 1719640
[No Abstract] [Full Text] [Related]
80. [Interferons in neurology].
Aguilar Rebolledo F
Rev Invest Clin; 2000; 52(6):665-79. PubMed ID: 11256110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
